Highline Capital Management
VC Fund
New York, United States
Highline Capital Management is a VC fund in New York focused on Biotechnology and Health Care. Highline Capital Management, L.P., is a New York City-based investment firm that focuses on mid and large capitalization U.S. equities long and short. Since its establishment in 1995, Highline has performed fundamental research to create portfolios with attractive risk/return profiles. Highline prides itself on producing a successfulrisk-adjusted track record relative to comparative U.S. equity market indices.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Highline Capital Management invests in
Stages Highline Capital Management invests in
Countries Highline Capital Management invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Jacob Doft
|
|||
Investment Focus
Industry
- Biotechnology 5 (71%)
- Health Care 4 (57%)
- Medical 3 (43%)
- Life Science 2 (29%)
- Therapeutics 2 (29%)
Stage
- Series C 2 (29%)
- Seed 1 (14%)
- Series A 1 (14%)
- Series B 1 (14%)
- Series D 1 (14%)
Country
- United States 5 (71%)
- Germany 1 (14%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Jacob Doft
Founder & CEO
|
Founder & CEO | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Network Bio
|
Network Bio is a clinical and molecular data library enabling precision medicine approaches for common human diseases. Its platform delivers a centralized repository for clinical and molecular data that allows researchers to identify patterns and correlations that can be used to develop new treatments and diagnostic tools. | $17M / Seed / Feb 27, 2025 | |
Proscia
|
Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team oftechnologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. | $9M / Series C / Mar 13, 2024 | |
|
Proscia
|
Proscia is a software company that is changing the way the world practices pathology to transform cancer research and diagnosis. With the company’s Concentriq digital pathology platform and pipeline of AI-powered applications, laboratories are leveraging new kinds of data to accelerate discoveries and improve patient outcomes. Proscia’s team oftechnologists, scientists, and pathologists is bringing a fresh approach to an outdated industry, helping the world to keep pace with the increasing demand for pathology services and fulfill the promise of precision diagnostics. | $36.6M / Series C / Jun 03, 2022 | |
Strata Oncology
|
Strata Oncology is a precision oncology company dedicated to transforming cancer care by expanding patient access to precision medicine clinical trials and accelerating drug approval. Strata's national precision oncology platform serves the needs of patients, providers and drug developers by providing a link from patient screening tostreamlined enrollment in mutation-matched clinical trials. Follow us on Twitter @StrataOncology. | $90M / Series C / Jul 28, 2021 | |
AtaiBeckley
|
ATAI is a global biotech company builder that leverages a decentralized, technology- and data-driven platform model to serve millions of people suffering from mental health disorders. The company is committed to acquiring and efficiently developing innovative treatments that address significant unmet medical needs and lead to paradigm shifts in themental health space.ATAI Life Sciences was founded in 2018 and is based in Munich, Bayern, Germany. | $157M / Series D / Mar 03, 2021 | |
Longboard Pharmaceuticals
|
Longboard Pharmaceuticals delivers medicines with optimized pharmacology and pharmacokinetics to patients with rare neurological diseases. Its proprietary pipeline includes multiple programs with broad clinical utility. Longboard is evaluating LP352, a next-generation 5-HT2C agonist, in development for the potential treatment of developmental andepileptic encephalopathies, or DEEs. Longboard is also evaluating LP143, a centrally acting, full agonist of the cannabinoid type 2 receptor (CB2), and LP659, a centrally acting, next-generation, highly selective S1P receptor modulator. | $56M / Series A / Oct 28, 2020 | |
Passage Bio
|
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $110M / Series B / Sep 04, 2019 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Highline Capital Management invest in?
Highline Capital Management invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Seed stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Highline Capital Management?
Public channels for Highline Capital Management include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Highline Capital Management?
The team at Highline Capital Management includes Jacob Doft (Founder & CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
